Human Microbiome Market

Human Microbiome Market Size, Share, Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2299 | Region: Global | Published Date: November, 2024
Pages: 201 | Tables: 90 | Figures: 74

Human Microbiome Market News

  • September 2022: Seres Therapeutics Inc. completed its BLA application to the FDA for SER-109 for the prevention of recurrent C. difficile infection (rCDI). This is a relatively new therapy that promises to improve current care for rCDI.
  • September 2022: Ferring Pharmaceuticals received a positive vote for RBX2660 from the FDA's Vaccine-Related Biological Products. Advisory Committee in an evaluation of a microbe-based survival biotherapy study for its ability to reduce recurrent C. difficile infection (CDI) after antibiotics.
  • In July 2021, Ceres Therapeutics Inc. entered into an agreement with Nestle Health Science to commercialize SER-109, an investigational microbiome delivery therapy for the treatment of recurrent Clostridioides difficile infection (CDI) in the United States (U.S.)
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Human Microbiome Market size was valued at USD 0.8 Billion in 2022 and is poised to grow from USD 1.01 Billion in 2023 to USD 9.7 Billion by 2031, growing at a CAGR of 31.80% during the forecast period (2024-2031).

A notable example of strategic engagement in the human microbiome market is the collaboration between Ceres Therapeutics and Nestle Health Science. This fellowship focuses on developing microbial therapies for a variety of health conditions, including gastrointestinal diseases. Nestlé’s investment and commercial potential, along with Ceres Therapeutics’ expertise in microbiology, will allow both companies to accelerate the development and commercialization of microbial-based therapies. 'Seres Therapeutics, Inc. (US) ', 'Ferring Pharmaceuticals (Switzerland) ', 'Biomebank (Australia) ', 'Nestlé S.A. (Switzerland) ', 'Sanofi (France) ', 'Seed Health, Inc. (US) ', 'Enterome (France) ', 'Pendulum (US) ', 'Quantbiome, Inc. (Dba Ombre) (US) ', 'Vedanta Biosciences, Inc. (US) ', 'Maat Pharma SA (France) ', 'International Flavors & Fragrances, Inc. (US) ', 'Optibiotx Health Plc (UK) ', 'Synlogic, Inc. (US) ', 'Guangzhou Zhiyi Biotechnology Co., Ltd. (China) ', 'Aobiome (US) ', 'Siolta Therapeutics (US) ', 'Alveolus Bio, Inc. (US) ', 'Mrm Health NV (Belgium) ', 'Biome Inc (US) ', 'Sanzyme Biologics (India) ', 'Biomx (Israel) ', 'Nubiyota (US) ', 'Quorum Innovations (US)'

The increasing prevalence of chronic diseases such as gastrointestinal disorders, obesity, and diabetes is a key driver for the human microbiome market as more and more studies link gut microbiota to these conditions, generating demand for treatment and research based on the microbiome. This growing interest from the physicians and patients is spurring investment in research, innovation, and commercialization of the small-scale products.

Increasing Focus on Personalized Medicine: The shift closer to customized medicinal drug is a trend inside the human microbiome market. Researchers and pharmaceutical groups have an increasing number of targeted on tailoring organic treatments to character sufferers based totally on their specific microbial composition. This trend is leading to more targeted healing procedures and diagnostics, paving the manner for extra powerful agents to deal with the microbiota-associated sicknesses.

North America is expected to account for most of the global human microbiome market. The dominance of this region prominence from the growing social problems and the growing identity of the next generation. For instance, the American Cancer Society, estimates in 2022 that approximately 1,918,030 new cancers had been identified inside the United States in 2022. Additionally, there are 274,364 new cancers and they may be expected to attain new populations 400,564 by 2040. Thus, such increasing cancer burden is anticipated to drive the marketplace increase as gut microbiota plays a valid position in tumor remedy along with the improving patient accessibility the immune machine and lowering the aspect outcomes of chemotherapy.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Human Microbiome Market

Report ID: SQMIG35H2299

$5,300
BUY NOW GET FREE SAMPLE